Hotgen Shines at Medic & Medlab East Africa 2025 with Comprehensive Diagnostic and TB Solutions

From October 22–24, 2025, Medic & Medlab East Africa, one of the most influential healthcare exhibitions in East Africa, was held in Nairobi, Kenya. As a leading Chinese IVD company, Hotgen Biotechnology showcased its full-scenario diagnostic portfolio, drawing strong attention from healthcare institutions and distributors across Kenya, Tanzania, Uganda, and beyond.

At the exhibition, Hotgen presented a lineup of its core and newly featured products:

MQ60 mono-test chemiluminescence series – designed for direct whole-blood testing, delivering results in 10 minutes with single-use packaging, perfectly suited for emergency and primary care;

C800 compact fully automated chemiluminescence immunoassay analyzer – offering efficient and cost-effective testing for small and medium-sized laboratories;

UPT2800 up-converting phosphor technology immunoassay analyzer – recognized for its high sensitivity and ease of use;

TB-IGRA (Interferon-Gamma Release Assay for Tuberculosis infection) and TB PCR POCT (Rapid Molecular Detection for TB) were showcased as key highlights, providing fast, accurate, and sensitive solutions for tuberculosis screening and diagnosis in Africa;

Additionally, colloidal gold rapid tests and ELISA kits formed part of Hotgen’s diverse diagnostic ecosystem, adaptable to multiple clinical scenarios.

In addition, Hotgen emphasized its commitment to local manufacturing and technology localization in Africa, promoting sustainable diagnostic capacity-building and enhancing access to high-quality testing across the region.

As a listed company on China’s STAR Market (Stock Code: 688068), Hotgen leveraged this exhibition to deepen partnerships in East Africa. With its innovative technologies and localized solutions, Hotgen is dedicated to empowering regional healthcare development and advancing medical diagnostics across Africa.